Literature DB >> 16152703

Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy.

William Lewis1.   

Abstract

NRTIs are cornerstones of antiretroviral therapy and perhaps the most important drugs developed for AIDS treatment. Judicious use of NRTIs in the fight against HIV infection has afforded significant clinical advances in AIDS treatment. Nonetheless, it is axiomatic to expect side effects from NRTIs as well. A principal toxicity of NRTIs relates to chronic and cumulative MT in various tissues. The long-term impact of this toxicity on affected patients is not clear except in extreme cases where morbidity was severe and mortality occurred. Because of chronicity and potential for severity, NRTI MT remains an important clinical problem. Further studies will help us unravel mechanisms of NRTI MT and the natural history of mitochondrial biogenesis in humans and other mammalian systems.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16152703

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  17 in total

1.  Decreased mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac targeted human mutant polymerase gamma.

Authors:  William Lewis; Brian J Day; James J Kohler; Seyed H Hosseini; Sherine S L Chan; Elgin C Green; Chad P Haase; Erin S Keebaugh; Robert Long; Tomika Ludaway; Rodney Russ; Jeffrey Steltzer; Nina Tioleco; Robert Santoianni; William C Copeland
Journal:  Lab Invest       Date:  2006-02-19       Impact factor: 5.662

2.  Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.

Authors:  Aura Temereanca; Luminita Ene; Adelina Rosca; Carmen C Diaconu; Anca Luca; Ruxandra Burlacu; Roxana Radoi; Adina Bulacu-Talnariu; Thomas D Marcotte; Cristian L Achim; Simona Ruta
Journal:  AIDS Res Hum Retroviruses       Date:  2019-10-08       Impact factor: 2.205

3.  Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART.

Authors:  W Todd Cade; Dominic N Reeds; Bettina Mittendorfer; Bruce W Patterson; William G Powderly; Samuel Klein; Kevin E Yarasheski
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-11-14       Impact factor: 4.310

4.  Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus.

Authors:  Hong-Wang Zhang; Steven J Coats; Lavanya Bondada; Franck Amblard; Mervi Detorio; Ghazia Asif; Emilie Fromentin; Sarah Solomon; Aleksandr Obikhod; Tony Whitaker; Nicolas Sluis-Cremer; John W Mellors; Raymond F Schinazi
Journal:  Bioorg Med Chem Lett       Date:  2009-11-13       Impact factor: 2.823

Review 5.  Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

Authors:  Lucette A Cysique; Bruce J Brew
Journal:  Neuropsychol Rev       Date:  2009-05-09       Impact factor: 7.444

6.  Zidovudine impairs adipogenic differentiation through inhibition of clonal expansion.

Authors:  Metodi V Stankov; Reinhold E Schmidt; Georg M N Behrens
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

7.  Cardiac-targeted transgenic mutant mitochondrial enzymes: mtDNA defects, antiretroviral toxicity and cardiomyopathy.

Authors:  James J Kohler; Seyed H Hosseini; Elgin Green; Amy Hoying-Brandt; Ioan Cucoranu; Chad P Haase; Rodney Russ; Jaya Srivastava; Kristopher Ivey; Tomika Ludaway; Victor Kapoor; Allison Abuin; Alexsey Shapoval; Robert Santoianni; Ann Saada; Orly Elpeleg; William Lewis
Journal:  Cardiovasc Toxicol       Date:  2008-04-30       Impact factor: 3.231

8.  Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.

Authors:  Akihiko Saitoh; Richard H Haas; Robert K Naviaux; Neurita G Salva; Justine K Wong; Stephen A Spector
Journal:  Antimicrob Agents Chemother       Date:  2008-06-09       Impact factor: 5.191

9.  Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1.

Authors:  Salina M Torres; Dale M Walker; Consuelo L McCash; Meghan M Carter; Jessica Ming; Edmund M Cordova; Rachel M Pons; Dennis L Cook; Steven K Seilkop; William C Copeland; Vernon E Walker
Journal:  Environ Mol Mutagen       Date:  2009-01       Impact factor: 3.216

10.  Tempol protects cardiomyocytes from nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity.

Authors:  Yongmin Liu; Eunwoo Shim; Phuonggiang Nguyen; Alexander T Gibbons; James B Mitchell; Miriam C Poirier
Journal:  Toxicol Sci       Date:  2014-03-03       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.